Nayara Rozalem Moretti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nayara Rozalem Moretti has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Cezar Aquino de Moraes
University of São Paulo
3 shared publications - Isabella Caroline de Oliveira Barretto
University of Western São Paulo, Presidente Prudente, Brazil
2 shared publications Ana Beatriz Nardelli da Silva
Federal University of Pará, 01 Augusto Corrêa St., Belém 66075-110, Brazil
1 shared publication- Ana Laura Ayumi Zanoni Chiba
Department of Medicine, University of Western São Paulo
1 shared publication - Angélica Augusta Grigoli Dominato
Universidade do Oeste Paulista
1 shared publication - Barbara Antonia Dups Talah
Pontifical Catholic University of Paraná, Curitiba, Brazil
1 shared publication
Latest Publications
- 17 October 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (4) , 1324-1339
Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis
Background Endometrial cancer (EC) is the sixth most common female cancer and may rank fourth in cancer mortality by 2040. TP53 mutations and aberrant p53 expression are associated to aggressive tumor subtypes and poor prognosis, reducing overall survival (OS), disease-free survival, recurrence rates (RcR) and Mortality Risk (MR). The prognostic impact of TP53 mutations in EC remains unclear. Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Library. Hazard ratios (HR) and Risk Ratios (RR) with 95% confidence intervals (CI) were combined using random-effects models. Analyses were conducted in RStudio (v4.4.1), and heterogeneity was evaluated using the I2 statistic, with p < 0.05 considered significant. Results Twenty-four studies comprising 5462 EC patients were included. TP53 mutations and aberrant p53 expression were associated with poorer outcomes. For OS, TP53 mutations had an HR of 2.27 (95% CI 1.47–3.49) and aberrant p53 had an HR of 5.01 (95% CI 2.44–10.30). For DFS, TP53 mutations had an HR of 4.20 (95% CI 1.79–9.86), while aberrant p53 had an HR of 2.17 (95% CI 1.27–3.72). TP53 mutations also increased RcR (RR: 2.88; 95% CI 2.18–3.80) and MR (RR: 2.33; 95% CI 1.11–4.88). Aberrant p53 showed a non-significant trend for recurrence (RR: 3.54; 95% CI 0.95–13.10). Conclusions TP53 mutations and abnormal p53 expression in EC patients predict a poorer prognosis, characterized by increased RcR and MR, as well as lower DFS and OS. Graphical abstract
- 17 October 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (4) , 1324-1339
Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis
Background Endometrial cancer (EC) is the sixth most common female cancer and may rank fourth in cancer mortality by 2040. TP53 mutations and aberrant p53 expression are associated to aggressive tumor subtypes and poor prognosis, reducing overall survival (OS), disease-free survival, recurrence rates (RcR) and Mortality Risk (MR). The prognostic impact of TP53 mutations in EC remains unclear. Methods A systematic search was conducted in PubMed, Embase, and the Cochrane Library. Hazard ratios (HR) and Risk Ratios (RR) with 95% confidence intervals (CI) were combined using random-effects models. Analyses were conducted in RStudio (v4.4.1), and heterogeneity was evaluated using the I2 statistic, with p < 0.05 considered significant. Results Twenty-four studies comprising 5462 EC patients were included. TP53 mutations and aberrant p53 expression were associated with poorer outcomes. For OS, TP53 mutations had an HR of 2.27 (95% CI 1.47–3.49) and aberrant p53 had an HR of 5.01 (95% CI 2.44–10.30). For DFS, TP53 mutations had an HR of 4.20 (95% CI 1.79–9.86), while aberrant p53 had an HR of 2.17 (95% CI 1.27–3.72). TP53 mutations also increased RcR (RR: 2.88; 95% CI 2.18–3.80) and MR (RR: 2.33; 95% CI 1.11–4.88). Aberrant p53 showed a non-significant trend for recurrence (RR: 3.54; 95% CI 0.95–13.10). Conclusions TP53 mutations and abnormal p53 expression in EC patients predict a poorer prognosis, characterized by increased RcR and MR, as well as lower DFS and OS. Graphical abstract
- 15 August 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 120
Therapeutic potential of extracellular vesicles in systemic lupus erythematosus: a systematic review
Current therapies for Systemic lupus erythematosus (SLE), such as immunosuppressants and glucocorticoids, are associated with significant side effects, necessitating alternative treatment approaches. Extracellular vesicles (EVs) have emerged as a potential therapeutic option due to their immunomodulatory properties and ability to regulate innate and adaptive immune responses. Thus, the objective of the present study was to systematically analyze the therapeutic potential of EVs for treating SLE. A systematic review was conducted according to PRISMA guidelines. An electronic search was performed in the PubMed/ MEDLINE, Scopus, Cochrane Library and Open Gray databases covering the period up to September 2024 to respond to the PICO answer "Would EVs have therapeutic potential in SLE?" Control of Systemic lupus erythematosus progression and the cellular and molecular mechanisms present were considered the primary and secondary outcome, respectively. The bias risk of studies was evaluated by SYRCLE's RoB. A total of 7 studies met the inclusion criteria, and the data exhibited that EVs reduced disease severity, improved survival rates and ameliorated organ-specific damage in SLE models. It was seen that EVs reduction of autoantibody, Th17 and Tfh cells, type-1 macrophage, neutrophils and pro-inflammatory cytokines, alongside an increase in Tregs, immunosuppressive cytokines and type-2 macrophage. The studies showed high scientific evidence. EV therapy exhibits potential in mitigating SLE progression by modulating immune responses and reducing inflammation. Further research is required to confirm these datas in humans, facilitating advancement for future clinical applications.
- 15 August 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 120
Therapeutic potential of extracellular vesicles in systemic lupus erythematosus: a systematic review
Current therapies for Systemic lupus erythematosus (SLE), such as immunosuppressants and glucocorticoids, are associated with significant side effects, necessitating alternative treatment approaches. Extracellular vesicles (EVs) have emerged as a potential therapeutic option due to their immunomodulatory properties and ability to regulate innate and adaptive immune responses. Thus, the objective of the present study was to systematically analyze the therapeutic potential of EVs for treating SLE. A systematic review was conducted according to PRISMA guidelines. An electronic search was performed in the PubMed/ MEDLINE, Scopus, Cochrane Library and Open Gray databases covering the period up to September 2024 to respond to the PICO answer "Would EVs have therapeutic potential in SLE?" Control of Systemic lupus erythematosus progression and the cellular and molecular mechanisms present were considered the primary and secondary outcome, respectively. The bias risk of studies was evaluated by SYRCLE's RoB. A total of 7 studies met the inclusion criteria, and the data exhibited that EVs reduced disease severity, improved survival rates and ameliorated organ-specific damage in SLE models. It was seen that EVs reduction of autoantibody, Th17 and Tfh cells, type-1 macrophage, neutrophils and pro-inflammatory cytokines, alongside an increase in Tregs, immunosuppressive cytokines and type-2 macrophage. The studies showed high scientific evidence. EV therapy exhibits potential in mitigating SLE progression by modulating immune responses and reducing inflammation. Further research is required to confirm these datas in humans, facilitating advancement for future clinical applications.
- 19 May 2025
- Published by Taylor & Francis in Biomarkers
- Vol. 30 (4) , 315-326
CYP450 gene polymorphisms and the risk of taxane-induced neurotoxicity in breast cancer patients: a systematic review and meta-analysis
Breast cancer (BC) is the most common cancer in women. Taxanes are widely used, but their neurotoxicity affects patients' quality of life. Genetic polymorphisms in CYP450 enzymes influence taxane metabolism, leading to variability in toxicity risk. A literature search was conducted to identify studies on the association between CYP450 polymorphisms and Taxane-Induced Peripheral Neuropathy (TIPN) in BC patients. Odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using a random-effects model in RStudio. Nine studies with 3034 patients were included. Overall CYP polymorphisms showed a significant association with TIPN (OR: 1.2877, 95% CI: 1.0262-1.6157). CYP1B1 polymorphism had an inconsistent link to TIPN by OR of 1.1524 (95% CI: 0.7441-1.7849). CYP2C8 polymorphism demonstrated the strongest association (OR: 1.5532, 95% CI: 1.2013-2.0082; HR: 1.5236, 95% CI: 1.1317-2.0512). CYP3A4 showed no significant association (OR: 1.0988, 95% CI: 0.5022-2.4404). CYP2C8 polymorphisms were significantly linked to TIPN. While CYP1B1 showed inconsistent results, CYP3A4 had no significant association. These findings imply that CYP2C8 genetic variations may affect taxane metabolism and neurotoxicity risk, indicating that pharmacogenomic profiling could help personalize chemotherapy and reduce adverse effects.
- 19 May 2025
- Published by Taylor & Francis in Biomarkers
- Vol. 30 (4) , 315-326
CYP450 gene polymorphisms and the risk of taxane-induced neurotoxicity in breast cancer patients: a systematic review and meta-analysis
Breast cancer (BC) is the most common cancer in women. Taxanes are widely used, but their neurotoxicity affects patients' quality of life. Genetic polymorphisms in CYP450 enzymes influence taxane metabolism, leading to variability in toxicity risk. A literature search was conducted to identify studies on the association between CYP450 polymorphisms and Taxane-Induced Peripheral Neuropathy (TIPN) in BC patients. Odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) were estimated using a random-effects model in RStudio. Nine studies with 3034 patients were included. Overall CYP polymorphisms showed a significant association with TIPN (OR: 1.2877, 95% CI: 1.0262-1.6157). CYP1B1 polymorphism had an inconsistent link to TIPN by OR of 1.1524 (95% CI: 0.7441-1.7849). CYP2C8 polymorphism demonstrated the strongest association (OR: 1.5532, 95% CI: 1.2013-2.0082; HR: 1.5236, 95% CI: 1.1317-2.0512). CYP3A4 showed no significant association (OR: 1.0988, 95% CI: 0.5022-2.4404). CYP2C8 polymorphisms were significantly linked to TIPN. While CYP1B1 showed inconsistent results, CYP3A4 had no significant association. These findings imply that CYP2C8 genetic variations may affect taxane metabolism and neurotoxicity risk, indicating that pharmacogenomic profiling could help personalize chemotherapy and reduce adverse effects.
- Open Access
- 15 December 2024
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 39 (1) , 1-14
Genomic mosaicism in colorectal cancer and polyposis syndromes: a systematic review and meta-analysis
Background: Colorectal cancer (CRC) and polypoid syndromes are significant public health concerns, with somatic mosaicism playing a crucial role in their genetic diversity. This study aimed to investigate the prevalence and impact of somatic mosaicism in these conditions. Methods: A search was conducted using PubMed, Scopus, and Web of Sciences to identify studies evaluating mosaicism in patients with CRC or polyposis syndromes. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to determine prevalence rates. Statistical analyses were performed using R software 4.3. Results: A total of 27 studies, encompassing 2272 patients, were included in the analysis. Of these, 108 patients exhibited somatic mosaicism, resulting in an overall prevalence of 8.79% (95% CI 5.1 to 14.70%, I2 = 85; p < 0.01). Subgroup analyses revealed a significantly higher prevalence of mosaicism in patients with APC mutations (OR 13.43%, 95% CI 6.36 to 26.18%, I2 = 87; p < 0.01). Additionally, mosaicism in MLH1 and MSH2 genes was observed at rates of 2.75% (95% CI 1.20 to 6.18%) and 9.69% (95% CI 2.98 to 27.24%), respectively. Conclusions: Our findings support the growing recognition of mosaicism as a critical factor in CRC susceptibility and underscore the importance of incorporating mosaicism screening into routine genetic testing for at-risk patients.
- 15 December 2024
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 39 (1) , 1-14
Open AccessGenomic mosaicism in colorectal cancer and polyposis syndromes: a systematic review and meta-analysis
Background: Colorectal cancer (CRC) and polypoid syndromes are significant public health concerns, with somatic mosaicism playing a crucial role in their genetic diversity. This study aimed to investigate the prevalence and impact of somatic mosaicism in these conditions. Methods: A search was conducted using PubMed, Scopus, and Web of Sciences to identify studies evaluating mosaicism in patients with CRC or polyposis syndromes. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to determine prevalence rates. Statistical analyses were performed using R software 4.3. Results: A total of 27 studies, encompassing 2272 patients, were included in the analysis. Of these, 108 patients exhibited somatic mosaicism, resulting in an overall prevalence of 8.79% (95% CI 5.1 to 14.70%, I2 = 85; p < 0.01). Subgroup analyses revealed a significantly higher prevalence of mosaicism in patients with APC mutations (OR 13.43%, 95% CI 6.36 to 26.18%, I2 = 87; p < 0.01). Additionally, mosaicism in MLH1 and MSH2 genes was observed at rates of 2.75% (95% CI 1.20 to 6.18%) and 9.69% (95% CI 2.98 to 27.24%), respectively. Conclusions: Our findings support the growing recognition of mosaicism as a critical factor in CRC susceptibility and underscore the importance of incorporating mosaicism screening into routine genetic testing for at-risk patients.
- 15 November 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 205, 104558
The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis
- 15 November 2024
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 205, 104558
The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis